Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. 1977

R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin

In the contact phase of activation of the kinin-forming, intrinsic clotting, and fibrinolytic systems, high-molecular-weight kininogen acts as a cofactor for the activation of Factor XI, prekallikrein, and Hageman factor. One mechanism by which high-molecular-weight kininogen acts as a cofactor has been studied by using 125I-labeled Factor XI and prekallikrein in kaolin-activated normal human plasma and plasmas deficient in high-molecular-weight kininogen and Hageman factor. High-molecular-weight kininogen was found to be essential for normal binding and cleavage of both Factor XI and prekallikrein on the kaolin surface. Hageman factor was essential for cleavage but not for binding of Factor XI and prekallikrein to kaolin. In normal plasma 80% of the activated Factor XI remained surface-bound, whereas 80% of the kallikrein was not surface-bound. These findings are consistent with the hypothesis that, in the initial phase of contact activation, high-molecular-weight kininogen links both Factor XI and prekallikrein to the exposed surface where they are activated by surface-bound activated Hageman factor. Once activated, the Factor XI molecules remain localized at the site of activation, in contrast to the kallikrein molecules which are found largely in the surrounding plasma.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007704 Kininogens Endogenous peptides present in most body fluids. Certain enzymes convert them to active KININS which are involved in inflammation, blood clotting, complement reactions, etc. Kininogens belong to the cystatin superfamily. They are cysteine proteinase inhibitors. HIGH-MOLECULAR-WEIGHT KININOGEN; (HMWK); is split by plasma kallikrein to produce BRADYKININ. LOW-MOLECULAR-WEIGHT KININOGEN; (LMWK); is split by tissue kallikrein to produce KALLIDIN. Cystatins, Kininogen,Kininogen,Prekinins,Prokinins,T-Kininogen,Thiostatin,Kininogen Cystatins,T Kininogen
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011288 Prekallikrein A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease. Fletcher Factor,Plasma Prokallikrein,Kallikreinogen,Plasma Prokallikrein A,Factor, Fletcher,Prokallikrein A, Plasma,Prokallikrein, Plasma
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005172 Factor XI Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C. Coagulation Factor XI,Plasma Thromboplastin Antecedent,Blood Coagulation Factor XI,Factor 11,Factor Eleven,Antecedent, Plasma Thromboplastin,Factor XI, Coagulation,Thromboplastin Antecedent, Plasma
D005175 Factor XII Deficiency An absence or reduced level of blood coagulation factor XII. It normally occurs in the absence of patient or family history of hemorrhagic disorders and is marked by prolonged clotting time. Hageman Trait,Coagulation Factor 12 Deficiency,Deficiency, Factor 12,Deficiency, Factor Twelve,Deficiency, Factor XII,Factor 12 Deficiency,Factor Twelve Deficiency,Hageman Factor Deficiency,Deficiencies, Factor 12,Deficiencies, Factor Twelve,Deficiencies, Factor XII,Deficiency, Hageman Factor,Factor 12 Deficiencies,Factor 12 Deficiency,Factor Deficiency, Hageman,Factor Twelve Deficiencies,Factor XII Deficiencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
January 2024, Journal of thrombosis and haemostasis : JTH,
R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
October 1979, Proceedings of the National Academy of Sciences of the United States of America,
R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
April 2017, Thrombosis and haemostasis,
R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
January 1987, Seminars in thrombosis and hemostasis,
R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
June 2003, The Journal of biological chemistry,
R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
August 1987, The Journal of biological chemistry,
R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
April 2002, Atherosclerosis,
R C Wiggins, and B N Bouma, and C G Cochrane, and J H Griffin
July 1977, The Journal of clinical investigation,
Copied contents to your clipboard!